# Contents

VOLUME 20 NUMBER 1 1ST JULY

1 Review article: targeted screening for hereditary haemochromatosis in high-risk groups. *S. DuBois & K. V. Kowdley*

15 Treatment of acute hepatitis C with interferon α-2b: early initiation of treatment is the most effective predictive factor of sustained viral response. *J. Delwaide, N. Bourgeois, C. Gérard, S. De Maeght, F. Mokaddem, E. Wain, B. Bastens, J. Fevery, M. Géhénot, O. Le Moine, J. P. Martinet, G. Robaeys, B. Servais, M. Van Gossum, H. Van Vlierberghe & The Belgian Association for the Study of the Liver (BASL)*

23 Metformin in the treatment of non-alcoholic steatohepatitis: a pilot open label trial. *S. Nair, A. M. Diehl, M. Wiseman, G. H. Farr Jr & R. P. Perrillo*

29 Pharmacokinetic variations of acetaminophen according to liver dysfunction and portal hypertension status. *P. Zapater, M. C. Lasso de la Vega, J. F. Horga, J. Such, R. Frances, A. Esteban, J. M. Palazòn, F. Carnicer, S. Pascual & M. Pérez-Mateo*

37 Pegylated interferon-α2a kinetics during experimental haemodialysis: impact of permeability and pore size of dialysers. *G. Barril, J. A. Quiroga, P. Sanz, F. Rodrìguez-Salvanés, R. Selgas & V. Carreño*

45 Clinical and histological features of non-alcoholic fatty liver disease in Hong Kong Chinese. *V. W.-S. Wong, H. L.-Y. Chan, A. Y. Hui, K.-F. Chan, C.-T. Liew, F. K.-L. Chan & J. J.-Y. Sung*

51 Therapeutic Arthritis Research and Gastrointestinal Event Trial of lumiracoxib – study design and patient demographics. *C. J. Hawkey, M. Farkouh, X. Gitton, E. Ehrsam, J. Huels & P. Richardson*

65 Azathioprine dose escalation in inflammatory bowel disease. *C. K. Rayner, A. L. Hart, C. M. M. Hayward, A. V. Emmanuel & M. A. Kamm*

73 Risk of vascular disease in adults with diagnosed coeliac disease: a population-based study. *J. West, R. F. A. Logan, T. R. Card, C. Smith & R. Hubbard*

81 Pathophysiological characteristics of patients with non-erosive reflux disease differ from those of patients with functional heartburn. *M. Frazzoni, E. De Micheli, P. Zentilin & V. Savarino*

89 The Visceral Sensitivity Index: development and validation of a gastrointestinal symptom-specific anxiety scale. *J. S. Labus, R. Bolus, L. Chang, I. Wiklund, J. Naesdal, E. A. Mayer & B. D. Naliboff*

99 Seven-day therapy for *Helicobacter pylori* in the United States. *N. Vakil, F. Lanza, H. Schwartz & J. Barth*

109 $^{13}$C-ethanol breath test reveals impaired alcohol metabolism in patients with *Helicobacter pylori* infection. *M. Suzuki, K. Maruyama, H. Suzuki, S. Tanaki, K. Suzuki & H. Ishii*

117 Masking of $^{13}$C urea breath test by proton pump inhibitors is dependent on type of medication: comparison between omeprazole, pantoprazole, lansoprazole and esomeprazole. *A. Levine, O. Shevah, V. Shabat-Sehayek, H. Aeed, M. Boaz, S. F. Moss, Y. Niv, Y. Avni & H. Shirin*

123 Letter to the Editors

Pegylated interferon-α-2b monotherapy for haemodialysis patients with chronic hepatitis

*C. B. E. Annicchiaroco & M. SicilianoB. E. Annichiarico & M. Siciliano*

Author's reply: *F. Fabrizi & P. Martin*

The treatment algorithm instead of the unknown optimal dose of botulinum toxin for chronic anal fissure. *M. Madalinski*

Author's reply: *G. Brisinda, F. Cadeddu, A. Mabisombi & G. Maria*

VOLUME 20 NUMBER 2 15TH JULY

129 Review article: hepatitis C virus-related extra-hepatic disease – aetiopathogenesis and management. *J. Medina, L. García-Buey & R. Moreno-Otero*

143 Systematic review: how effective are the usual treatments for ulcerative colitis? *J. R. Bebb & B. B. Scott*

151 Systematic review: how effective are the usual treatments for Crohn's disease? *J. R. Bebb & B. B. Scott*

161 Efficacy and safety of thiopurinic immunomodulators (azathioprine and mercaptopurine) in steroid-dependent ulcerative colitis. *A. Lopez-Sanroman, F. Bermejo, E. Carrera & A. Garcia-Plaza*

167 Improvement in quality of life of children with acute Crohn's disease does not parallel mucosal healing after treatment with exclusive enteral nutrition. *N. A. Afzal, H. J. van der Zaag-Loonen, F. Arnaud-Battandier, S. Davies, S. Murch, B. Derkx, R. Heuschkel & J. M. Fell*

173 Hyperamylasaemia and acute pancreatitis in paracetamol poisoning. *L. E. Schmidt & K. Dalhoff*

181 Six-month trial of on-demand rabeprazole 10 mg maintains symptom relief in patients with non-erosive reflux disease. *P. Bytzer, A. Blum, D. De Herdt & D. Dubois, on behalf of the trial investigators*

189 Wireless capsule endoscopy in patients with obscure gastrointestinal bleeding: a comparative study with push enteroscopy. *A. Mata, J. M. Bordas, F. Feu, A. Ginés, M. Pellisé, G. Fernández-Esparrach, F. Balaguer, J. M. Piqué & J. Llach*

195 The cost-effectiveness of high-dose oral proton pump inhibition after endoscopy in the acute treatment of peptic ulcer bleeding. *A. N. Barkun, K. Herba, V. Adam, W. Kennedy, C. A. Fallone & M. Bardou*

203 Risks of interleukin-1 genetic polymorphisms and *Helicobacter pylori* infection in the development of gastric cancer. *A. Chen, C.-N. Li, P.-I. Hsu, K.-H. Lai, H.-H. Tseng, P.-N. Hsu, G.-H. Lo, C.-C. Lo, C.-K. Lin, I.-R. Hwang, Y. Yamaoka & H.-C. Chen*

213 The effects of withdrawing tegaserod treatment in comparison with continuous treatment in irritable bowel syndrome patients with abdominal pain/discomfort, bloating and constipation: a clinical study. *K. D. Bardhan, A. Forbes, C. L. Marsden, T. Mason & G. Short*

223 Alosetron repeat dose pharmacokinetics, effects on enzyme activities, and influence of demographic factors. *K. M. Koch, B. W. Corrigan, J. Manzo, C. D. James, R. J. Scott, A. G. Stead & K. E. Kersey*

231 Anti-ganglioside antibodies in children with coeliac disease: correlation with gluten-free diet and neurological complications. *C. Briani, S. Ruggero, G. Zara, E. Toffanin, M. Ermani, C. Betterle & G. Guariso*

237 Effect of asimadoline, a $\kappa$ opioid agonist, on pain induced by colonic distension in patients with irritable bowel syndrome. *M. Delvaux, A. Beck, J. Jacob, H. Bouzamondo, F. T. Weber & J. Frexinos*

247 Letter to the Editors. *F. Özgenç, B. Dikici & R. V. Yagci*

VOLUME 20 NUMBER 3 1ST AUGUST

249 Review article: the evolving role of liver biopsy. *M. S. Campbell & K. R. Reddy*

261 Review article: *Helicobacter pylori* and molecular events in precancerous gastric lesions. *G. Nardone, A. Rocco & P. Malfertheiner*

271 Review article: hepatic hydrothorax. *A. Cardenas, T. Kelleher & S. Chopra*

281 Four years of treatment with lamivudine: clinical and virological evaluations in HBe antigen-negative chronic hepatitis B. *S. Gaia, A. Marzano, A. Smedile, V. Barbon, M. L. Abate, A. Olivero, M. Lagget, S. Paganin, M. Fadda, G. Niro & M. Rizzetto*

289 Increased thrombin generation and circulating levels of tumour necrosis factor-α in patients with chronic *Helicobacter pylori*-positive gastritis. *A. Consolazio, M. C. Borgia, D. Ferro, F. Iacopini, O. A. Paoluzi, P. Crispino, F. Nardi, M. Rivera & P. Paoluzi*

295 *Helicobacter pylori* eradication in children and adolescents by a once daily 6-day treatment with or without a proton pump inhibitor in a double-blind randomized trial. *Y. Tindberg, T. H. Casswall, M. Blennow, C. Bengtsson, M. Granström & M. Sörberg*

303 Tumour necrosis factor-α receptor 1 and 2 polymorphisms in inflammatory bowel disease and their association with response to infliximab. *M. Pierik, S. Vermeire, K. V. Steen, S. Joossens, G. Claessens, R. Vlietinck & P. Rutgeerts*

311 Health-related quality of life of patients with gastrointestinal symptoms. *H. J. Bovenschen, R. J. F. Laheij, A. C. I. T. L. Tan, E. M. Witteman, L. G. M. van Rossum & J. B. M. J. Jansen*

321 Economic analysis of strategies in the prevention of non-steroidal anti-inflammatory drug-induced complications in the gastrointestinal tract. *A. Lanas*

333 Effect of the motilin agonist KC 11458 on gastric emptying in diabetic gastroparesis. *A. Russo, J. E. Stevens, N. Giles, G. Krause, D. G. O'Donovan, M. Horowitz & K. L. Jones*

339 Prevalence of irritable bowel syndrome according to different diagnostic criteria in a non-selected adult population. *M. T. Hillilä & M. A. Färkkilä*

347 *In vivo* evaluation of a novel pH- and time-based multiunit colonic drug delivery system. *C. Bott, M. W. Rudolph, A. R. J. Schneider, S. Schirrmacher, B. Skalsky, H.-U. Petereit, P. Langguth, J. B. Dressman & J. Stein*

355 A new questionnaire for constipation and faecal incontinence. *A. E. Bharucha, G. R. Locke III, B. M. Seide & A. R. Zinsmeister*

365 Reproducibility of a symptom response to omeprazole therapy in functional dyspepsia evaluated by a random-starting-day trial design. *L. G. Madsen & P. Bytzer*

VOLUME 20 NUMBER 4 15TH AUGUST

373 Systematic review: the hepatotoxicity of non-steroidal anti-inflammatory drugs. *J. H. Rubenstein & L. Laine*

381 Personal view: 'Don't ask, don't tell' – the undesirable consequences of incidental test results in gastroenterology. *A. Sonnenberg*

389 Personal view: rationale and proposed algorithms for symptom-based proton pump inhibitor therapy for gastro-oesophageal reflux disease. *P. Bytzer & A. L. Blum*

399 Intragastric acid suppression and pharmacokinetics of twice-daily esomeprazole: a randomized, three-way crossover study. *P. O. Katz, D. O. Castell, Y. Chen, T. Andersson & M. B. Sostek*

407 A novel option in proton pump inhibitor dosing: lansoprazole orally disintegrating tablet dispersed in water and administered via nasogastric tube. *J. W. Freston, M. J. Kukulka, E. Lloyd & C. Lee*

413 The role of acid suppression in patients with endoscopy-negative reflux disease: the effect of treatment with esomeprazole or omeprazole. *D. Armstrong, N. J. Talley, K. Lauritsen, B. Moum, T. Lind, H. Tunturi-Hihnala, T. Venables, J. Green, M. A. Bigard, J. Mössner & O. Junghard*

423 Identifying response to acid suppressive therapy in functional dyspepsia using a random starting day trial – is gastro-oesophageal reflux important? *L. G. Madsen, L. Wallin & P. Bytzer*

431 Pneumatic balloon dilatation in achalasia: a prospective comparison of safety and efficacy with different balloon diameters. *J. Mikaeli, F. Bishehsari, G. Montazeri, M. Yaghoobi & R. Malekzadeh*

437 Erythropoietin increases platelet reactivity and platelet counts in patients with alcoholic liver cirrhosis: a randomized, double-blind, placebo-controlled study. *M. Homoncik, P. Jilma-Stohlawetz, M. Schmid, A. Ferlitsch & M. Peck-Radosavljevic*

445 The impact of immigration on the increasing incidence of hepatocellular carcinoma in the United States. *K. Kulkarni, E. Barcak, H. El-Serag & R. Goodgame*

451 Treatment of gastro-oesophageal reflux disease with rabeprazole in primary and secondary care: does *Helicobacter pylori* infection affect proton pump inhibitor effectiveness? *N. J. Wit, W. A. de Boer, H. Geldof, B. Hazelhoff, P. Bergmans, G. N. J. Tytgat & A. J. P. M. Smout*

459 The validity and accuracy of the Work Productivity and Activity Impairment questionnaire – irritable bowel syndrome version (WPAI:IBS). *M. C. Reilly, A. Bracco, J.-F. Ricci, J. Santoro & T. Stevens*

469 A rapid immunochromatographic assay for *Helicobacter pylori* in stool before and after treatment. *L. Gatta, F. Perna, C. Ricci, J. F. Osborn, A. Tampieri, V. Bernabucci, M. Miglioli & D. Vaira*

475 Successful treatment of oesophageal candidiasis by micafungin: a novel systemic antifungal agent. *K. Pettengell, J. Mynhardt, T. Kluyts, W. Lau, D. Facklam& D. Buell, the FK463 South African study group*

VOLUME 20 NUMBER 5 1ST SEPTEMBER

483 Systematic review: has disease outcome in Crohn's disease changed during the last four decades? *F. L. Wolters, M. G. V. M. Russel & R. W. Stockbrügger*

497 Relationship between body mass index, diet, exercise and gastro-oesophageal reflux symptoms in a community. *S. Nandurkar, G. R. Locke III, S. Fett, A. R. Zinsmeister, A. J. Cameron & N. J. Talley*

507 Projections of demand and capacity for colonoscopy related to increasing rates of colorectal cancer screening in the United States. *S. Vijan, J. Inadomi, R. A. Hayward, T. P. Hofer & A. M. Fendrick*

517 Effect of acid on duodenal blood flow and mucus secretion measured by reflectance spectrophotometry: a prospective, randomized-controlled study. *F. C. Ramirez, J. F. Holland, J. Harker & F. W. Leung*

527 Reduced incidence of upper gastrointestinal ulcer complications with the COX-2 selective inhibitor, valdecoxib. *J. L. Goldstein, G. M. Eisen, N. Agrawal, W. F. Stenson, J. D. Kent & K. M. Verburg*

539 Adjuvant biofeedback following anal sphincter repair: a randomized study. *K. J. Davis, D. Kumar & J. Poloniecki*

551 Fracture risk of women with primary biliary cirrhosis: no increase compared with general population controls. *J. R. Boulton-Jones, R. M. F. Fenn, J. West, R. F. A. Logan & S. D. Ryder*

559 *Helicobacter pylori* infection prevents the occurrence of the tolerance phenomenon of histamine H2 receptor antagonists. *T. Fujisawa, K. Adachi, Y. Komazawa, T. Mihara, T. Azumi, T. Katsube, K. Furuta, H. Kazumori & Y. Kinoshita*

567 Prevention of erosive oesophagitis relapse with pantoprazole. *J. E. Richter, P. Fraga, M. Mack, S. M. Sabesin W. Bochenek & the Pantoprazole US GERD Study Group*

577 Use of anti-secretory medication: a population-based cohort study. *A. Lassen, J. Hallas & O. B. Schaffalitzky de Muckadell*

585 Basic fibroblast growth factor as a response parameter to infliximab in fistulizing Crohn's disease. *Q. Gao, R. A. van Hogezand, C. B. H. W. Lamers & H. W. Verspaget*

VOLUME 20 NUMBER 6 15TH SEPTEMBER

593 Cost-effectiveness of thiopurine methyltransferase genotype screening in patients about to commence azathioprine therapy for treatment of inflammatory bowel disease *J. Winter, A. Walker, D. Shapiro, D. Gaffney, R. J. Spooner & P. R. Mills*

601 Azathioprine formulation optimizes metabolite profile in inflammatory bowel disease *T. Stevens, J. P. Achkar, K. Easley, A. Brzezinski & B. Lashner*

607 Rapid improvement of bone metabolism after infliximab treatment in Crohn's disease *N. Franchimont, V. Putzeys, J. Collette, S. Vermeire, P. Rutgeerts, M. De Vos, A. Van Gossum, D. Franchimont, R. Fiasse, P. Pelckmans, M. Malaise, J. Belaiche & E. Louis*

615 Diagnostic accuracy of faecal calprotectin estimation in prediction of abnormal small bowel radiology *S. Dolwani, M. Metzner, J. J. Wassell, A. Yong & A. B. Hawthorne*

623 A pilot study of orlistat treatment in obese, non-alcoholic steatohepatitis patients *S. A. Harrison, C. Fincke, D. Helinski, S. Torgerson & P. Hayashi*

629 Combination therapy for the treatment of hepatitis C in the veteran population: higher than expected rates of therapy discontinuation *Y. Getachew, J. D. Browning, M. Prebis, T. Rogers & G. R. Brown*

637 Oesophageal and gastric pH profiles in patients with gastro-oesophageal reflux disease and Barrett's oesophagus treated with proton pump inhibitors *L. B. Gerson, V. Boparai, N. Ullah & G. Triadafilopoulos*

645 Daily use of non-steroidal anti-inflammatory drugs is less frequent in patients with Barrett's oesophagus who develop an oesophageal adenocarcinoma *P. Tsibouris, M. T. Hendrickse & P. E. T. Isaacs*

657 Esomeprazole 20 mg on-demand is more acceptable to patients than continuous lansoprazole 15 mg in the long-term maintenance of endoscopy-negative gastro-oesophageal reflux patients: the COMMAND Study. *H. H. Tsai, R. Chapman, A. Shepherd, D. McKeith, M. Anderson, D. Vearer, S. Duggan & J. P. Rosen*

667 Long-term outcome and objective changes of anorectal function after biofeedback therapy for faecal incontinence *R. Ozturk, S. Niazi, M. Stessman & S. S. C. Rao*

675 Effect of cyclo-oxygenase inhibitors on *Helicobacter pylori* susceptibility to metronidazole and clarithromycin *Q. Gu, H. H.-X. Xia, W. H. Wang, J. D. Wang, W. M. Wong, A. O. O. Chan, M. F. Yuen, S. K. Lam, H. K.-L. Cheung, X. G. Liu & B. C.-Y. Wong*

683 Effects of effervescent ranitidine on gastric pH: comparison with almagate and placebo in fasting and postprandial conditions *E. Rey, C. Poves-Francés, G. Sánchez, A. Fueyo, C. Badiola & M. Díaz-Rubio*

689 Differential effects of two types of antidepressants, amitriptyline and fluoxetine, on anorectal motility and visceral perception *L. Siproudhis, M. Dinasquet, V. Sébille, J. M. Reymann & E. Bellissant*

697 Letters to the Editors
Epidemiology of ischaemic colitis *A. Brinker & M. Avigan*
Author's reply *L. Laine & P. D. R. Higgins*

701 Corrigenda

703 Erratum

VOLUME 20 NUMBER 7 1ST OCTOBER

705 Systematic review: geographical and ethnic differences in gastro-oesophageal reflux disease. *J. Y. Kang*

719 Review article: the role of the hiatus hernia in gastro-oesophageal reflux disease. *C. Gordon, J. Y. Kang, P. J. Neild & J. D. Maxwell*

733 Systematic review: the effect of *Helicobacter pylori* and its eradication on gastro-oesophageal reflux disease in patients with duodenal ulcers or reflux oesophagitis. *A. S. Raghunath, A. P. S. Hungin, D. Wooff & S. Childs*

745 Meta-analysis: budesonide treatment for collagenous colitis. *B. Feyen, G. C. Wall, E. P. Finnerty, J. E. DeWitt & R. S. Reyes*

751 Natural history of gastro-oesophageal reflux disease diagnosed in general practice. *A. Ruigómez, L. A. García Rodríguez, M.-A. Wallander, S. Johansson, H. Graffner & J. Dent*

761 There is no difference in the disease severity of gastro-oesophageal reflux disease between patients infected and not infected with *Helicobacter pylori*. *C. A. Fallone, A. N. Barkun, S. Mayrand, G. Wakil, G. Friedman, A. Szilagyi, C. Wheeler & D. Ross*

769 Risk of malignancy in diagnosed coeliac disease: a 24-year prospective, population-based, cohort study. *T. R. Card, J. West & G. K. T. Holmes*

777 Psychological support counselling improves gluten-free diet compliance in coeliac patients with affective disorders. *G. Addolorato, G. De Lorenzi, L. Abenavoli, L. Leggio, E. Capristo & G. Gasbarrini*

783 Granulocyte and monocyte adsorptive apheresis in the treatment of active distal ulcerative colitis: a prospective, pilot study. *T. Yamamoto, S. Umegae, T. Kitagawa, Y. Yasuda, Y. Yamada, D. Takahashi, M. Mukumoto, N. Nishimura, K. Yasue & K. Matsumoto*

793 Barrett's oesophagus with predominant intestinal metaplasia correlates with superficial cyclo-oxygenase-2 expression, increased proliferation and reduced apoptosis: changes that are partially reversed by non-steroidal anti-inflammatory drugs usage. *Y. Amano, S. Ishihara, Y. Kushiyama, T. Yuki, Y. Takahashi, D. Chinuki, T. Miyake, Y. Miyaoka, M. A. K. Rumi, N. Ishimura, K. Adachi & Y. Kinoshita*

803 Onset and disappearance of reflux symptoms in a Chinese population: a 1-year follow-up study. *W. M. Wong, K. C. Lai, K. F. Lam, W. M. Hui, J. Q. Huang, H. H. X. Xia, W. H. C. Hu, C. L. K. Lam, C. K. Chan, S. K. Lam & B. C. Y. Wong*

813 Intestinal inflammation is a frequent feature of cystic fibrosis and is reduced by probiotic administration. *E. Bruzzese, V. Raia, G. Gaudiello, G. Polito, V. Buccigrossi, V. Formicola & A. Guarino*

821 Letter to the Editors

Gluten-related cerebral hypoperfusion and neurologic disorders in coeliac patients. *L. Leggio, L. Abenavoli, C. D'Angelo, D. Di Giuda, G. Gasbarrini & G. Addolorato*

Reply *C. Birani*

Anti-*Saccharomyces cerevisiae* antibodies and response to infliximab in refractory Crohn's disease. *O. Schröder, M. Naumann & J. Stein*

VOLUME 20 NUMBER 8 15TH OCTOBER

825 Review article: Pegylated interferons: chemical and clinical differences. *G. R. Foster*

831 Review article: therapeutic roles of acupuncture in functional gastrointestinal disorders. *H. Ouyang & J. D. Z. Chen*

843 Increased incidence of azathioprine-induced pancreatitis in Crohn's disease compared with other diseases. *R. K. Weersma, F. T. M. Peters, L. E. Oostenbrug, A. P. van den Berg, M. van Haastert, R. J. Ploeg, M. D. Posthumus, J. J. Homan van der Heide, P. L. M. Jansen & H. M. van Dullemen*

851 Effect of antitumour necrosis factor-α therapy on bone turnover in patients with active Crohn's disease: a prospective study. *B. M. Ryan, M. G. V. M. Russel, L. Schurgers, M. Wichers, J. Sijbrandij, R. W. Stockbrugger & E. Schoon*

859 Nicotine enemas for treatment of ulcerative colitis: a study of the pharmacokinetics and adverse events associated with three doses of nicotine. *J. R. Ingram, P. Routledge, J. Rhodes, R. W. Marshall, D. C. Buss, B. K. Evans, C. Feyerabend & G. A. O. Thomas*

867 Treatment of Budd-Chiari syndrome in a Liver Transplant Unit, the role of transjugular intrahepatic porto-systemic shunt and liver transplantation. *A. Attwell, M. Ludkowski, R. Nash & M. Kugelmas*

875 Dwell time and functional failure in percutaneous endoscopic gastrostomy tubes: a prospective randomized-controlled comparison between silicon polymer and polyurethane percutaneous endoscopic gastrostomy tubes. *J. Blacka, J. Donoghue, M. Sutherland, I. Martincich, S. Mitten-Lewis, P. Morris & G. Meredith*

883 Intravenous and oral lansoprazole are equivalent in suppressing stimulated acid output in patient volunteers with erosive oesophagitis. *T. O. G. Kovacs, C. Q. Lee, Y.-L. Chiu, B. L. Pilmer & D. C. Metz*

891 International validation of ReQuest in patients with endoscopy-negative gastro-oesophageal reflux disease. *K. D. Bardhan, V. Stanghellini, D. Armstrong, P. Berghöfer, G. Gatz & H. Mönnikes*

899 Effect of low-dose rabeprazole and omeprazole on gastric acidity: results of a double blind, randomized, placebo-controlled, three-way crossover study in healthy subjects. *S. Bruley des Varannes, H. Gharib, V. Bicheler, R. Bost, B. Bonaz, L. Stanescu, J. C. Delchier & S. Bonnot-Marlier*

909 Non-cardiac chest pain: predictors of health care seeking, the types of health care professional consulted, work absenteeism and interruption of daily activities. *G. D. Eslick & N. J. Talley*

# Contents

VOLUME 20 NUMBER 9 1ST NOVEMBER

917 Review article: the management of side-effects during therapy for hepatitis C. *R. J. Aspinall & P. J. Pockros*

931 Meta-analysis: a randomized trial of peginterferon plus ribavirin for the initial treatment of chronic hepatitis C genotype 4. *M. S. Khuroo, M. S. Khuroo & S. T. Dahab*

939 Personal view: cost and benefit of medical rituals in gastroenterology. *A. Sonnenberg*

943 A prospective, randomized-controlled pilot study of ursodeoxycholic acid combined with mycophenolate mofetil in the treatment of primary sclerosing cholangitis. *R. K. Sterling, J. J. Salvatori, V. A. Luketic, A. J. Sanyal, A. S. Fulcher, R. T. Stravitz, M. J. Contos, A. S. Mills & M. L. Shiffman*

951 Rapid hip bone loss in active Crohn's disease patients receiving short-term corticosteroid therapy. *J. H. Tobias, M. R. Sasi, R. Greenwood & C. S. J. Probert*

959 Behaviour of the bowel wall during the first year after surgery is a strong predictor of symptomatic recurrence of Crohn's disease: a prospective study. *F. Parente, G. M. Sampietro, M. Molteni, S. Greco, A. Anderloni, C. Sposito, P. G. Danelli, A. M. Taschieri, S. Gallus & G. Bianchi Porro*

969 Sleep dysfunction in patients with gastro-oesophageal reflux disease: prevalence and response to GERD therapy, a pilot study. *N. Chand, D. A. Johnson, M. Tabangin & J. C. Ware*

975 A single dose of ranitidine 150 mg modulates oesophageal acid sensitivity in patients with functional heartburn. *S. Rodriguez-Stanley, A. A. Ciociola, S. Zubaidi, H. M. Proskin & P. B. Miner Jr*

983 The new DR-70 immunoassay detects cancer of the gastrointestinal tract: a validation study. *A. Kerber, J. Trojan, K. Herrlinger, D. Zgouras, W. F. Caspary & B. Braden*

989 Are patients' sedation preferences at gastroscopy influenced by preceding patients' decisions? . *A. Olithselvan, A. S. McIntyre & D. A. Gorard*

VOLUME 20 NUMBER 10 15TH NOVEMBER


993 Review article: current status of liver transplantation in HIV-infected patients. *G. W. Neff, K. E. Sherman, B. Eghtesad & J. Fung*

1001 Review article: $^{13}$C-urea breath test in the diagnosis of *Helicobacter pylori* infection. *J. P. Gisbert & J. M. Pajares*

1019 Review article: orofacial granulomatosis. *J. C. Leão, T. Hodgson, C. Scully & S. Porter*

1029 Review article: is there a link between micronutrient malnutrition and *Helicobacter pylori* infection?. *J. Salgueiro, M. Zubillaga, C. Goldman, A. Barrado, M. Martinez Sarrasague, N. Leonardi & J. Boccio*

1035 A systematic review: Is ingestion of paracetamol or non-steroidal anti-inflammatory drugs associated with exacerbations of inflammatory bowel disease? *K. Forrest, D. Symmons & P. Foster*

1045 Meta-analysis: the diagnostic value of alarm symptoms for upper gastrointestinal malignancy. *G. A. J. Fransen, M. J. R. Janssen, J. W. M. Muris, R. J. F. Laheij & J. B. M. J. Jansen*

1053 Meta-analysis: the effect of age on immunological response to hepatitis B vaccine in end-stage renal disease. *F. Fabrizi, P. Martin, V. Dixit, S. Bunnapradist & G. Dulai*

1063 Meta-analysis: the detection of pancreatic malignancy with positron emission tomography. *L. A. Orlando, S. L. Kulasingam & D. B. Matchar*

1071 Meta-analysis: the efficacy, adverse events, and adherence related to first-line anti-*Helicobacter pylori* quadruple therapies. *L. A. Fischbach, S. V. van Zanten & J. Dickason*

1083 A novel diagnostic tool for detecting oesophageal pathology: the PillCam oesophageal video capsule. *R. Eliakim, K. Yassin, I. Shlomi, A. Suissa & G. M. Eisen*

1091 Proton-pump inhibitors reduce the risk of uncomplicated peptic ulcer in elderly either acute or chronic users of aspirin/non-steroidal anti-inflammatory drugs. *A. Pilotto, M. Franceschi, G. Leandro, F. Paris, L. Cascavilla, M. G. Longo, V. Niro, A. Andriulli, C. Scarcelli & F. Di Mario*

1099 Esomeprazole 40 mg i.v. provides faster and more effective intragastric acid control than pantoprazole 40 mg i.v.: results of a randomized study. *C. H. Wilder-Smith, K. Röhss, P. Bondarov, B. Hallerbäck, L.-E. Svedberg & H. Ahlbom*

1105 Pantoprazole provides rapid and sustained symptomatic relief in patients treated for erosive oesophagitis. *W. J. Bochenek, M. E. Mack, P. D. Fraga & D. C. Metz*

1115 Outcomes in elderly patients following surgery for colorectal cancer in the veterans affairs health care system. *L. Rabeneck, J. A. Davila, M. Thompson & H. B. El-Serag*

1125 Clinical experience of patients undergoing photodynamic therapy for Barrett's dysplasia or cancer. *H. C. Wolfsen, L. L. Hemminger, M. B. Wallace & K. R. DeVault*

1133 Randomized placebo-controlled trial assessing the effect of bifidobacteria-fermented milk on active ulcerative colitis. *K. Kato, S. Mizuno, Y. Umesaki, Y. Ishii, M. Sugitani, A. Imaoka, M. Otsuka, O. Hasunuma, R. Kurihara, A. Iwasaki & Y. Arakawa*

1143 Anti-*Saccharomyces cerevisiae* mannan antibodies in inflammatory bowel disease: comparison of different assays and correlation with clinical features. *V. Annese, A. Piepoli, F. Perri, G. Lombardi, A. Latiano, G. Napolitano, G. Corritore, P. Vandewalle, D. Poulain, J. F. Colombel & A. Andriulli*

1153 Symptomatic gastro-oesophageal reflux, arousals and sleep quality in patients undergoing polysomnography for possible obstructive sleep apnoea. *N. Guda, S. Partington & N. Vakil*

1161 Do physicians correctly assess patient symptom severity in gastro-oesophageal reflux disease? *C. A. Fallone, G. H. Guyatt, D. Armstrong, I. Wiklund, A. Degl'Innocenti, D. Heels-Ansdell, A. N. Barkun, N. Chiba, S. J. O. van Zanten, S. El-Dika, P. Austin, L. Tanser & H. J. Schünemann*

1171 Classification of dyspepsia and response to treatment with proton-pump inhibitors. *V. Meineche-Schmidt*

1181 *Bacillus clausii* therapy to reduce side-effects of anti-*Helicobacter pylori* treatment: randomized, double-blind, placebo controlled trial. *E. C. Nista, M. Candelli, F. Cremonini, I. A. Cazzato, M. A. Zocco, F. Franceschi, G. Cammarota, G. Gasbarrini & A. Gasbarrini*

1189 High-dose vitamin E supplementation does not diminish ribavirin-associated haemolysis in hepatitis C treatment with combination standard α-interferon and ribavirin. *K. Saeian, J. S. Bajaj, J. Franco, J. F. Knox, J. Daniel, C. Peine, D. McKee, R. R. Varma, S. Ho & and Midwest Hepatitis Study Group*

1195 Comorbidity of irritable bowel syndrome in general practice: a striking feature with clinical implications. *P. O. Vandvik, I. Wilhelmsen, C. Ihlebæk & P. G. Farup*

1205 Agreements among traditional Chinese medicine practitioners in the diagnosis and treatment of irritable bowel syndrome. *J. J. Y. Sung, W. K. Leung, J. Y. L. Ching, L. Lao, G. Zhang, J. C. Y. Wu, S. M. Liang, H. Xie, Y. P. Ho, L. S. Chan, B. Berman & F. K. L. Chan*

# Contents

VOLUME 20 NUMBER 11/12 DECEMBER

1211 Review article: nucleoside analogues for the treatment of chronic hepatitis B. *H. M. Younger, A. J. Bathgate & P. C. Hayes*

1231 Review article: the eosinophil as a therapeutic target in gastrointestinal disease. *S. P. Hogan & M. E. Rothenberg*

1241 Systematic review: is there excessive use of proton pump inhibitors in gastro-oesophageal reflux disease? *T. J. Lee, M. B. Fennerty & C. W. Howden*

1253 Meta-analysis: the treatment of irritable bowel syndrome. *D. Lesbros-Pantoflickova, P. Michetti, M. Fried, C. Beglinger & A. L. Blum*

1271 Meta-analysis: effect of hepatitis C virus infection on mortality in dialysis. *F. Fabrizi, P. Martin, V. Dixit, S. Bunnapradist & G. Dulai*

1279 Meta-analysis: phytotherapy of functional dyspepsia with the herbal drug preparation STW 5 (Iberogast). *J. Melzer, W. Rösch, J. Reichling, R. Brignoli & R. Saller*

1289 Endoscopic ablation of Barrett's oesophagus: a randomized-controlled trial of photodynamic therapy vs. argon plasma coagulation. *C. J. Kelty, R. Ackroyd, N. J. Brown, T. J. Stephenson, C. J. Stoddard & M. W. R. Reed*

1297 Irritable bowel, smoking and oesophageal acid exposure: an insight into the nature of symptoms of gastro-oesophageal reflux. *J. Zimmerman*

1305 The usual medical care for irritable bowel syndrome. *W. E. Whitehead, R. L. Levy, M. Von Korff, A. D. Feld, O. S. Palsson, M. Turner & D. A. Drossman*

1317 Intestinal permeability in patients with irritable bowel syndrome after a waterborne outbreak of acute gastroenteritis in Walkerton, Ontario. *J. K. Marshall, M. Thabane, A. X. Garg, W. Clark, J. Meddings & S. M. Collins for the WEL Investigators*

1323 A prospective assessment of cytomegalovirus infection in active inflammatory bowel disease. *P. de Saussure, A. Lavergne-Slove, M.-C. Mazeron, S. Alain, C. Matuchansky & Y. Bouhnik*

1329 Clinical and endosonographic effect of ciprofloxacin on the treatment of perianal fistulae in Crohn's disease with infliximab: a double-blind placebo-controlled study. *R. L. West, C. J. van derWoude, B. E. Hansen, R. J. F. Felt-Bersma, A. J. P. van Tilburg, J. A. G. Drapers & E. J. Kuipers*

1337 Intravenous CDP870, a PEGylated Fab′ fragment of a humanized antitumour necrosis factor antibody, in patients with moderate-to-severe Crohn's disease: an exploratory study. *T. A. Winter, J. Wright, S. Ghosh, J. Jahnsen, A. Innes & P. Round*

1347 Granulocyteaphaeresis in steroid-dependent inflammatory bowel disease: a prospective, open, pilot study. *E. Domènech, J. Hinojosa, M. Esteve-Comas, F. Gomollón, J. M. Herrera, G. Bastida, A. Obrador, R. Ruiz, C. Saro & M. A. Gassull for The Spanish Group for the Study of Crohn's Disease & Ulcerative Colitis (GETECCU)*

1353 Mesalazine (5-aminosalicylic acid) micropellets show similar efficacy and tolerability to mesalazine tablets in patients with ulcerative colitis – results from a randomized-controlled trial. *A. Raedler, C. Behrens & P. Bias*

1365 Ultrase MT12 and Ultrase MT20 in the treatment of exocrine pancreatic insufficiency in cystic fibrosis: safety and efficacy. *M. W. Konstan, R. C. Stern, J. R. Trout, J. M. Sherman, H. Eigen, J. S. Wagener, C. Duggan, M. E. B. Wohl & P. Colin*

1373 Oesophageal pH has a power-law distribution in control and gastro-oesophageal reflux disease subjects. *J. D. Gardner, S. Sloan, M. Robinson & P. B. Miner*

1381 Frequency analyses of gastric pH in control and gastro-oesophageal reflux disease subjects treated with a proton-pump inhibitor. *J. D. Gardner, S. Sloan, M. Robinson & P. B. Miner Jr*

1387 Corrigenda

1389 Erratum

1391 Index